Sold as Tissueblue. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Brilliant Blue G (sold as Tissueblue), first approved Dec 20, 2019, with 0 new uses approved and 0 published complete response letters.
| Comparison Between Outcomes of Closure of Idiopathic Macular Hole Using Autologus Tenon Capsule Graft and Internal Limiting Membrane Flap Techniques (Pilot Study)Macular Hole Surgery, ILM Peeling · Ain Shams University | Not applicable | Recruiting | Jun 8, 2026 |
| Mechanical Properties of the Internal Limiting Membrane and Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted ChromovitrectomyMacular Edema · University Hospital, Basel, Switzerland | — | Recruiting | Dec 5, 2011 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 20, 2019 | TissueblueNDA 209569 · New molecular entity | Dutch Ophthalmic | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA